THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/603,094
Applicant : Don J. DIAMOND
Filed : June 25, 2003

TC/A.U. : 1645

Examiner : To Be Assigned

Docket No. : 1954-410 Customer No. : 06449 Confirmation No. : 7356

## INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent and Trademark Office P.O. Box 1450 Alexandria, Virginia 22313-1450

## Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith copies of publications that the Office may wish to consider in examination of the subject application. The publications are listed on the attached form PTO-1449. Reference CCCC is a book the table of contents of which is provided. Applicants will provide any section of this reference upon request.

Respectfully submitted,

Вy

Martha Cassidy

Attorney for Applicants/ Registration No. 44,060

ROTHWELL, FIGG, ERNST /& MANBECK, p.c.

Suite 800, 1425 K Street, N.W.

Washington, D.C. 20005 Telephone: (202)783-6040

Enclosure(s): PTO-1449 Form References

| · · · · · · · · · · · · · · · · · · ·         | / 0 ·                    | PE                          | E         |          |        |                              |                                     | Complete if Known                               | <br>)        |  |      |
|---|--------------------------|-----------------------------|-----------|----------|--------|------------------------------|-------------------------------------|---|--------------|--|------|
| 1   | MAR 0 8 2004             |                             |           |          |        |                              | tion Number                         |   |              |  |      |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT |                          |                             |           |          |        | iling D                      |                                     | June 25, 2003                                   |              | · <del>-</del> · · · · · · · · · · · · · · · · · · ·   |      |
|   |                          |                             |           |          |        | irst Na                      | med Inventor                        | Don J. DIAMON                                   | D            |  |      |
|   |                          |                             |           |          |        | Froup A                      | Art Unit                            | 1645  |              |  |      |
|   |                          |                             |           |          | E      | xamin                        | er Name                             | To Be Assigned                                  |              |  |      |
| Sheet   | 1                        |                             | of        | 8        | A      | ttorney                      | / Docket Number                     | 1954-410  |              |  |      |
|   |                          |                             |           |          | U.S    | . PATE                       | NT DOCUMENTS                        |   |              |  |      |
|   |                          | ,                           | U.S. Pate | ent Docu | ment   |                              | Name of Pate                        | entee or Applicant                              |              | Date of Publication                                    | 1    |
| Examiner<br>Initials*                         | Cite<br>No. <sup>1</sup> |                             | Numbe     | r        | Kind ( |                              | of Cited                            | d Document                                      |              | Date of Publication of Cited Document MM-DD-YYYY       |      |
|   | A.                       | 6,156,3                     | 17        |          |        |                              | Diamond et al.                      |   |              | 12-05-2000   |      |
|   | В.                       | 6,074,64                    | 45        |          |        |                              | Diamond et al.                      |   |              | 06-13-2000   |      |
|   |                          | <u> </u>                    |           |          |        |                              |                                     |   |              |  |      |
|   |                          |                             |           |          |        |                              |                                     |   |              |  |      |
|   |                          |                             | _         |          |        |                              |                                     |   |              |  |      |
|   |                          |                             |           |          |        |                              |                                     |   |              |  | ···· |
|   |                          |                             |           |          |        |                              |                                     |   |              |  | -    |
|   | <b>.</b>                 | <u> </u>                    |           | F        | OREI   | GN PA                        | TENT DOCUMEN                        | TS  |              | <u>.                                    </u>           |      |
|   |                          |                             | Foreign I | Patent D | ocume  | nt                           |                                     |   |              | As of Dublication of                                   |      |
| Examiner Initials*                            | Cite<br>No.1             | Office <sup>3</sup><br>Code |           | Numb     |        | <br>Kind⁵<br><i>f known)</i> | Citod F                             | Name of Patentee of Applicant of Cited Document |              | Date of Publication of<br>Cited Document<br>MM-DD-YYYY |      |
|   | C.                       | wo                          | 00/75     | 180      |        | A2                           | Florian Kern                        |   | 12-          | -14-2000   |      |
|   | D.                       | wo                          | 94/00     | 150      | · · ·  | A1                           | City of Hope                        |   | 01-          | -06-1994   |      |
|   | E.                       | wo                          | 97/40     | 165      |        | A1                           | The Wistar Instit                   | tute of Anatomy                                 | 10-          | -30-1997   |      |
|   | F.                       | wo                          | 98/260    | 074      | _      | A1                           | Institut National<br>La Recherche M | De La Sante et de<br>ledicale                   | 06-          | -18-1998   |      |
|   | G.                       | wo                          | 99/193    | 349      |        | A1                           | City of Hope                        |   | 04           | -22-1999   |      |
| Examiner<br>Signature                         |                          | <u> </u>                    | <u> </u>  |          |        |                              |                                     | Date<br>Considered                              | <del>1</del> |  |      |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

|                       |              | •                      | 1                        |                                 |  | Complete if Known   |                |  |
|-----------------------|--------------|------------------------|--------------------------|---------------------------------|--|---|----------------|--|
| · · ·                 |              |                        |                          |                                 | Application Number   | 10/603,094  |                |  |
| INFOR                 |              |                        | SCLOS<br>APPLIC          |                                 | Filing Date June 25, 2003  |   |                |  |
| 0 5 1 261             | <u> છે</u>   | <b>.</b>               |                          |                                 | First Named Inventor   | Don J. DIAMOND  |                |  |
| MAR 0 8 2004          | ب <u>بر</u>  |                        |                          |                                 | Group Art Unit   | 1645  | •              |  |
| b                     |              |                        |                          |                                 | Examiner Name  | To Be Assigned  |                |  |
| Sheet                 | 2            |                        | of                       | 8                               | Attorney Docket Number   | 1954-410  |                |  |
|                       |              |                        |                          | NON PA                          | TENT LITERATURE DOCUI  | MENTS   |                |  |
| Examiner Initials*    | Cite<br>No.1 |                        |                          |                                 |  | of the article (when appropriate), title of the etc.), date, page(s), volume-issue number(s), there published | T <sup>2</sup> |  |
|                       | H.           |                        |                          |                                 |  | ersal DR-Restricted Helper Epitopes by<br>iity 1:751-761, December 1994.                                      |                |  |
|                       | 1.           |                        |                          |                                 |  | ic Mice: Functional CTL Repertoire and nal of Immunology 159:4753-4761, 1997.                                 |                |  |
|                       | J.           |                        | an, John D<br>oer 4, 199 |                                 | enotypic Analysis of Antigen-Sp  | ecific T Lymphocytes," <u>Science</u> 274:94-96,  |                |  |
|                       | K.           |                        |                          |                                 | oecific CD8 <sup>+</sup> T Cells Produce Ar<br><u>Med</u> . 192(1):63-75, July 3, 2000 | ntiviral Cytokines but are Impaired in<br>).  |                |  |
|                       | L.           | Banc<br>to CD<br>2001. | 34⁺ Proge                | acques, et al<br>enitor-derived | ., "Immune and Clinical Respon<br>I Dendritic Cell Vaccine," <u>Cance</u>              | nses in Patients with Metastatic Melanoma<br>er Research 61:6451-6458, September 1,                           |                |  |
|                       | M.           |                        |                          |                                 |  | isease and viral load in gut reservoir and ne 7(12):1320-1326, December 2001.                                 |                |  |
|                       | N.           | A*020                  | 01/DR1 Tr                |                                 | ce: Dependence on HLA Class  | <i>I</i> linimal Epitope Vaccine in HLA<br>Il Restricted T <sub>H</sub> Response," <u>Human</u>               |                |  |
|                       | О.           |                        |                          |                                 | I., "Intranasal administration of esponses," <u>Immunology</u> 106:11                  | a synthetic lipopeptide without adjuvant<br>3-121, 2002.  |                |  |
|                       | P.           | Persi                  | stence of                |                                 | ed Autologous T Cells in a Nonl  | ssive Regimen Prolongs In Vivo<br>human Primate Model," <u>Journal of Virology</u>                            |                |  |
|                       | Q.           |                        |                          |                                 | oxic T Lymphocytes from HLA-A<br>" <u>J. Exp. Med.</u> 168:1157-1162,                  | A2 Transgenic Mice Specific for HLA-A2<br>September 1988.   |                |  |
|                       | R.           |                        |                          |                                 | "Human Cytomegalovirus-Spec<br>eneration and Specificity," <u>Eur.</u>                 | cific Cytotoxic T Lymphocytes:<br>J. Immunol. 13:804-809, 1983.   |                |  |
|                       | S.           | Type                   | 1 envirev                | <b>DNA Vaccin</b>               |  | eers with a Human Immunodeficiency Virus<br>liferation and Lymphocyte Production of β-<br>83, 2000.           |                |  |
| Examiner<br>Signature |              |                        |                          |                                 |  | Date<br>Considered  |                |  |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

| ,                     |              | •   | ,                                 |                                  |  | Complete if Ki                            | nown  |                |  |
|-----------------------|--------------|---|-----------------------------------|----------------------------------|--|---|---|----------------|--|
|                       |              |   |                                   |                                  | Application Number   | 10/603,094                                |   |                |  |
| OSTATI                |              |   | SCLOS                             |                                  | Filing Date June 25, 2003  |   |   |                |  |
| OOIAI                 | <u> </u>     | 2.,   | W 1 E.O                           |                                  | First Named Inventor   | Don J. DIAN                               | MOND  |                |  |
| MAR 0 8 2004          | , <u>ii</u>  |   |                                   |                                  | Group Art Unit   | 1645                                      |   |                |  |
| TRADE Sheet           | \$ /         |   |                                   |                                  | Examiner Name  | To Be Assig                               | gned  | · · · ·        |  |
| Sheet                 | 3            |   | of                                | 8                                | Attorney Docket Number   | 1954-410                                  |   |                |  |
|                       | •            |   |                                   | NON PA                           | TENT LITERATURE DOCUI  | MENTS                                     |   |                |  |
| Examiner<br>Initials* | Cite<br>No.1 | i   |                                   |                                  | thor (in CAPITAL LETTERS), title o<br>urnal, serial, symposium, catalog, e<br>publisher, city and/or country w | tc.), date, page(s                        |   | T <sup>2</sup> |  |
|                       | Т.           | Chu, f<br>Immui   | Rose S., enity," <u>J. E</u>      | et al., "CpG (<br>kp. Med. 186   | Oligodeoxynucleotides Act as A<br>(10):1623-1631, November 17,   | djuvants that S<br>, 1997.                | witch on T Helper 1 (Th1)                               |                |  |
|                       | U.           |   |                                   |                                  | ect Visualization of Cytomegalo<br>plantation," <u>Blood</u> 97(5):1232-1:                                     |   |   |                |  |
|                       | V.           |   |                                   |                                  | oG DNA Is a Potent Enhancer of urface Antigen," The Journal of   |   |   |                |  |
|                       | W.           | Class   |                                   | es Depends                       | fficient Processing of an Antige<br>on Its Neighboring Residues in   |   |   |                |  |
|                       | X.           | Del Va<br>Vaccir<br>1991.   | al, Margar<br>ne Contai           | ita, et al., "P<br>ning a Single | rotection Against Lethal Cytome<br>Nonameric T-Cell Epitope," <u>Jc</u>  | egalovirus Infection                      | ction by a Recombinant<br>gy 65(7):3641-3646, July      |                |  |
|                       | Y.           |   |                                   |                                  | o priming of a virus-specific of ture 342:561-564, Novembe   |   | nphocytes with synthetic                                |                |  |
|                       | Z.           |   |                                   |                                  | velopment of a Candidate HLA<br>lood 90(5):1751-1767, Septemb  |   | cted Peptide Based Vaccine                              |                |  |
|                       | AA.          |   |                                   |                                  | fusion of Cytomegalovirus (CM ing to Antiviral Chemotherapy,"  |   |   |                |  |
|                       | BB.          | Freyta<br>236, 1  |                                   | t al., "Bacter                   | ial Toxins as Mucosal Adjuvant   | s," <u>Curr. Top. M</u>                   | Aicrobiol. Immunol. 236:215-                            |                |  |
|                       | CC.          | Huma  | y-Ségard<br>n Immund<br>ary 2000. | , Hanne, et a                    | al., "Multiepitopic B- and T-Cell l<br>/irus Type 1 Lipopeptide Vaccin   | Responses Ind<br>ne," <u>Journal of \</u> | uced in Humans by a<br><u>/irology</u> 74(4):1694-1703, |                |  |
|                       | DD.          | Lymph   | nocytes in                        | T-Cell-Depl                      | etramer-based Quantification of<br>eted Stem Grafts and after Trar<br>on," <u>Blood</u> 98(5):1358-1364, Se    | nsplantation Ma                           | ay Identify Patients at Risk                            |                |  |
|                       | EE.          | Grefte, J.M., et al., "The Lower Matrix Protein pp65 is the Principal Viral Antigen Present in Periphera Blood Leukocytes During an Active Cytomegalovirus Infection," <u>Journal of General Virology</u> 73:2923-2932, 1992. |                                   |                                  |  |   |   |                |  |
|                       | FF.          | IE1-E   | kon4, gB,                         | pp150, and                       | oxic T Lymphocyte (CTL) Respo<br>pp28 in Healthy Individuals: Re<br><u>Diseases</u> 181:1537-46, 2000.         | onses to Huma<br>evaluation of P          | n Cytomegalovirus pp65,<br>revalence of IE1-Specific    |                |  |
| Examiner<br>Signature |              |   |                                   |                                  | or not citation is in conformance  | Date<br>Considered                        |   |                |  |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

|                            |             | , | •                        |                                     |  | Complete if K      | nown                               |                |
|----------------------------|-------------|---|--------------------------|-------------------------------------|--|--------------------|------------------------------------|----------------|
|                            |             |   |                          |                                     | Application Number   | 10/603,094         |                                    |                |
|                            |             |   | ISCLOS<br>APPLIC         |                                     | Filing Date June 25, 2003  |                    |                                    |                |
| 6 1918 TEMENT BY APPLICANT |             |   |                          |                                     | First Named Inventor   | Don J. DIA         | MOND                               |                |
| MAR 0 8 2004               | <u> </u>    |   |                          |                                     | Group Art Unit   | 1645               |                                    |                |
| <br>                       |             |   |                          |                                     | Examiner Name  | To Be Assi         | gned                               |                |
| Sheet                      | 4           |   | of                       | 8                                   | Attorney Docket Number   | 1954-410           |                                    |                |
|                            |             |   |                          | NON PA                              | TENT LITERATURE DOCU   | MENTS              |                                    |                |
| Examiner<br>Initials*      | Cite<br>No. |   |                          |                                     | thor (in CAPITAL LETTERS), title o<br>urnal, serial, symposium, catalog, e<br>publisher, city and/or country w | tc.), date, page(s |                                    | T <sup>2</sup> |
|                            | GG.         |   | ∕o by Carri              |                                     | ning of Anti-Human Immunodef<br>Synthetic Peptides," <u>Proc. Natl</u>   |                    |                                    |                |
|                            | нн.         |   |                          |                                     | Pilot Study of the CY-1899 T-C<br>atology 30(2):531-536, August  |                    | Subjects Chronically Infected      |                |
|                            | II.         |   |                          |                                     | he Use of HLA A2.1/p53 Peptic<br>ertoire," The Journal of Immuno   |                    |                                    |                |
|                            | JJ.         |   |                          |                                     | parison of Adjuvant Formulation<br>e 14(5):412-418, 1996.  | ns for Cytotoxic   | T Cell Induction Using             |                |
|                            | KK.         |   | onses Aga                |                                     | Immunostimulatory DNA-Based<br>Systemic and Mucosal Sites," <u>T</u>   |                    |                                    |                |
|                            | LL.         |   |                          |                                     | lization of MHC Class I Transge<br>HLA-Restricted CTL Epitopes,  |                    |                                    |                |
|                            | MM.         |   |                          |                                     | is of CD8 T Cell Reactivity to C<br>decapeptides," <u>Eur. J. Immuno</u>                                       |                    |                                    |                |
|                            | NN.         |   | lodalton M               |                                     | Structures of the CD8*-T-Cell I ate-Early Protein Revisited," J.   |                    |                                    |                |
|                            | 00.         |   |                          | et al., "CpG<br><u>unol.</u> 247:13 | DNA Augments the Immunoger<br>1-142, 2000.   | nicity of Plasmi   | d DNA Vaccines," <u>Curr. Top.</u> |                |
|                            | PP.         |   | , Arthur M<br>09-760, 20 |                                     | 6 Motifs in Bacterial DNA and T  | heir Immune E      | ffects," Annu. Rev. Immunol.       |                |
|                            | QQ.         |   |                          | ., et al., "Cp0<br>), April 6, 199  | G Motifs in Bacterial DNA Trigge<br>95.  | er Direct B-Cell   | Activation," Nature                |                |
|                            | RR.         |   |                          |                                     | nancing Vaccines with Immune ):15-24, 2001.  | Stimulatory Cp     | G DNA," <u>Current Opinion in</u>  |                |
| Examiner<br>Signature      |             |   |                          |                                     |  | Date<br>Considered |                                    |                |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

|                       |              |  |  | (   | Complete if Kı                    | nown  |                |  |  |  |  |
|-----------------------|--------------|--|--|---|-----------------------------------|---|----------------|--|--|--|--|
| , '                   |              |  |  | Application Number  | 10/603,094                        |   |                |  |  |  |  |
|                       |              | ON DISCLOSU<br>TBY APPLICA   |  | Filing Date   | June 25, 20                       | 03  |                |  |  |  |  |
| SIAI                  |              | DIAIILIOA  | A14 1  | First Named Inventor  | Don J. DIAMOND                    |   |                |  |  |  |  |
|                       |              |  |  | Group Art Unit  | 1645                              |   |                |  |  |  |  |
|                       |              |  |  | Examiner Name   | To Be Assigned                    |   |                |  |  |  |  |
| Sheet                 | 5            | of   | 8  | Attorney Docket Number  | 1954-410                          |   |                |  |  |  |  |
|                       |              |  | NON PA   | TENT LITERATURE DOCUM   | MENTS                             |   |                |  |  |  |  |
| Examiner<br>Initials* | Cite<br>No.1 |  |  | hor (in CAPITAL LETTERS), title of<br>urnal, serial, symposium, catalog, e<br>publisher, city and/or country wh | tc.), date, page(s                |   | T <sup>2</sup> |  |  |  |  |
|                       | SS.          |  |  | equence Motifs in Adenovira<br>Proc. Natl. Acad. Sci. USA 9   |                                   |   |                |  |  |  |  |
|                       | TT.          |  | d from Po  | 'Enhanced Immune Activity of sitional Scanning Synthetic Color, 2001.   |                                   |   |                |  |  |  |  |
|                       | UU.          | Responses After  | Li, Cheng-Rong, et al., "Recovery of HLA-Restricted Cytomegalovirus (CMV)-Specific T-Cell Responses After Allogeneic Bone Marrow Transplant: Correlation with CMV Disease and Effect of Ganciclovir Prophylaxis," Blood 83(7):1971-1979, 1994. |   |                                   |   |                |  |  |  |  |
|                       | VV.          | Limaye, Ajit P., el<br>Transplant Recip<br>2002.   | t al., "High<br>ients Rece   | Incidence of Ganciclovir-Resist iving Preemptive Therapy," The  | ant Cytomegale<br>Journal of Infe | ovirus Infection among Lung<br>ectious Diseases 185:20-7, |                |  |  |  |  |
|                       | ww.          | Lipford, G.B., et a<br>Papilloma Virus T   | al. "Peptide<br>Tumour Ant   | Engineering Allows Cytotoxic Titigen, E6," <u>Immunology</u> 84:298-  | Γ-cell Vaccinati<br>303, 1995.    | on Against Human  |                |  |  |  |  |
|                       | XX.          |  |  | CpG-containing synthetic oligor<br>n: a new class of vaccine adjuva   |                                   |   |                |  |  |  |  |
|                       | YY.          | Livingston, Brian D., et al. "Altered Helper T Lymphocyte Function Associated with Chronic Hepatitis B Virus Infection and its Role in Response to Therapeutic Vaccination in Humans," <u>J. Immunology</u> 162:3088-3095, 1999. |  |   |                                   |   |                |  |  |  |  |
|                       | ZZ.          |  | cination Are   | The Hepatitis B Virus-Specific (<br>Comparable to Those Elicited<br>2, 1997.                                    |                                   |   |                |  |  |  |  |
|                       | AAA.         |  |  | opulation Coverage by HLA Cla<br>52:165-173, 2001.  | ss-I Restricted                   | Cytotoxic T-Lymphocyte                                    |                |  |  |  |  |
|                       | BBB.         | Ludewig, Burkhai<br><u>Virology</u> 72(5):38   |  | Dendritic Cells Efficiently Induce<br>May 1998.   | Protective Ant                    | iviral Immunity," <u>Journal of</u>                       |                |  |  |  |  |
|                       | CCC.         | Adjuvant: Immune   | e Respons  | nmunization of Mice with Lipopo<br>e of BALB/c Mice to Human Im<br>of Immunology 149(10):3416-34                | munodeficiency                    | / Virus Envelope  |                |  |  |  |  |
|                       | DDD.         |  |  | , "Mucosal Immunization of Mic<br>scherichia coli as Adjuvants," <u>\</u>                                       |                                   |   |                |  |  |  |  |
| Examiner<br>Signature |              |  |  |   | Date<br>Considered                |   |                |  |  |  |  |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Unique citation designation number. 2Applicant is to place a check mark here if English language Translation is attached.

|   | <del> </del> | _   | •  |  |  | Complete if K                    | nown   |                |  |  |  |  |
|---|--------------|-----|--|--|--|----------------------------------|--|----------------|--|--|--|--|
| •   |              |     |  |  | Application Number   | 10/603,094                       |  |                |  |  |  |  |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT |              |     |  |  | Filing Date  | June 25, 20                      | 03   |                |  |  |  |  |
|   |              |     |  |  | First Named Inventor   | Don J. DIAN                      | MOND   |                |  |  |  |  |
|   |              |     |  |  | Group Art Unit   | 1645                             |  |                |  |  |  |  |
|   |              |     |  |  | Examiner Name  | To Be Assigned                   |  |                |  |  |  |  |
| Sheet   | 6            |     | of   | 8  | Attorney Docket Number   | 1954-410                         |  |                |  |  |  |  |
|   |              |     |  | NON PA                                       | TENT LITERATURE DOCU   | MENTS                            |  |                |  |  |  |  |
| Examiner<br>Initials*                         | Cite<br>No.1 |     | Include<br>item (bool  | name of the a<br>k, magazine, j              | uthor (in CAPITAL LETTERS), title<br>ournal, serial, symposium, catalog,<br>publisher, city and/or country | etc.), date, page                | en appropriate), title of the (s), volume-issue number(s),   | T <sup>2</sup> |  |  |  |  |
|   | EEE.         | Pro | tein pp65  | Taylor, Elizat<br>as a Target<br>ogy 43:103- | peth, et al., "Identification of the<br>Antigen for CD8* Virus-Specific<br>110, 1994.                      | Major Late Hui<br>Cytotoxic T Ly | man Cytomegalovirus Matrix<br>rmphocytes," <u>Journal of</u> |                |  |  |  |  |
|   | FFF.         | Imr | mune Res   |  | t, et al., "CpG DNA Can Induce<br>st Hepatitis B Surface Antigen i<br>per 1998.                            |                                  |  |                |  |  |  |  |
|   | GGG.         |     | Moldoveanu, Zina, et al., "CpG DNA, a Novel Immune Enhancer for Systemic and Mucosal mmunization with Influenza Virus," <u>Vaccine</u> , 16(11/12):1216-1224, 1998   |  |  |                                  |  |                |  |  |  |  |
|   | ннн.         |     |  |  | trolled Lipidation and Encapsul<br>The Journal of Immunology 161   |                                  |  |                |  |  |  |  |
|   | III.         | CT  |  |  | ffectiveness of Intranasal Immu<br>in Combination with the Mucos   |                                  |  |                |  |  |  |  |
|   | JJJ.         | HIV | Newman, M.J., et al., "Induction of Cross-reactive Cytotoxic T-lymphocyte Responses Specific for HIV-1 gp120 Using Saponin Adjuvant (QS-21) Supplemented Subunit Vaccine Formulations," <a href="Vaccine">Vaccine</a> 15(9):1001-1007, 1997.   |  |  |                                  |  |                |  |  |  |  |
|   | KKK.         | Cyt | Nichols, W. Garrett, et al., "High Risk of Death Due to Bacterial and Fungal Infection among Cytomegalovirus (CMV)-Seronegative Recipients of Stem Cell Transplants from Seropositive Donors: Evidence for Indirect Effect of Primary CMV Infection," The Journal of Infectious Diseases 185:273-82, 2002. |  |  |                                  |  |                |  |  |  |  |
|   | LLL.         |     |  |  | man Cytomegalovirus Strain To<br>a coli," <u>Virology</u> 182: 220-228, 1                                  |                                  | e: Nucleotide Sequence and                                   |                |  |  |  |  |
|   | MMM.         |     |  |  | L Responses Induced by a Sing<br>articles," <u>Journal of Immunologi</u>                                   |                                  |  |                |  |  |  |  |
|   | NNN.         |     | lependent  |  | , "Scheme for Ranking Potentiandividual Peptide Side-Chains,"  |                                  |  |                |  |  |  |  |
|   | 000.         |     | mmensee<br>(4):178-22  |  | g, et al., "MHC Ligands and Pe   | ptide Motifs: Fir                | st Listing," <u>Immunogenetics</u> ,                         |                |  |  |  |  |
|   | PPP.         |     |  | , Hans-Geor<br>ol. 11:213-44                 | g, et al., "Peptides Naturally Pro<br>, 1993.  | esented by MH                    | C Class I Molecules," <u>Annu.</u>                           |                |  |  |  |  |
| Examiner<br>Signature                         |              |     |  |  |  | Date<br>Considered               |  |                |  |  |  |  |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Unique citation designation number. 2Applicant is to place a check mark here if English language Translation is attached.

| ,                     |              |   |  |   |   | Complete if Kn                    | own                        |                |  |  |  |  |
|-----------------------|--------------|---|--|---|---|-----------------------------------|----------------------------|----------------|--|--|--|--|
| • '                   |              |   |  |   | Application Number  | 10/603,094                        |                            |                |  |  |  |  |
|                       |              | N DISCI   |  |   | Filing Date   | June 25, 2003                     |                            |                |  |  |  |  |
| STATI                 | EMENI        | BY APF  | LIC  | ANI                                     | First Named Inventor  | Don J. DIAMOND                    |                            |                |  |  |  |  |
|                       |              |   |  |   | Group Art Unit  | 1645                              |                            |                |  |  |  |  |
|                       |              |   |  |   | Examiner Name   | To Be Assigned                    |                            |                |  |  |  |  |
| Sheet                 | 7            |   | of   | 8                                       | Attorney Docket Number  | 1954-410                          |                            |                |  |  |  |  |
|                       |              |   |  | NON PA                                  | TENT LITERATURE DOCUM   | MENTS                             |                            |                |  |  |  |  |
| Examiner<br>Initials* | Cite<br>No.1 |   |  |   | thor (in CAPITAL LETTERS), title cournal, serial, symposium, catalog, epublisher, city and/or country w                                     | etc.), date, page(s               |                            | T <sup>2</sup> |  |  |  |  |
|                       | QQQ.         |   |  |   | e Response to Human Cytor<br>unology 154:222-254 (1990)   |                                   | fection," Current Topics   |                |  |  |  |  |
|                       | RRR.         | Reece, J<br>Emerging  | eann<br>g Pict   | ette, et al., "I<br>ure," <u>J. Imm</u> | Mapping the Major Human T He<br>unol. 151(11):6175-6184, Dece   | lper Epitopes of<br>mber 1, 1993. | f Tetanus Toxin: the       |                |  |  |  |  |
|                       | SSS.         | Using Au  | itolog   | ous B-Lympi                             | Generation of Cytomegalovirus-<br>noblastoid Cells with Stable Exp<br>of the Antiviral Response," <u>J. of</u>                              | ression of pp65                   | or IE1 Proteins: a Tool to |                |  |  |  |  |
|                       | тт.          | Infected  | Riddell, Stanley, et al., "Class I MHC-Restricted Cytotoxic T Lymphocyte Recognition of Cells Infected with Human Cytomegalovirus does not Require Endogenous Viral Gene Expression," <u>J. Immunology</u> 146(8):2795-2804, April 15, 1991. |   |   |                                   |                            |                |  |  |  |  |
|                       | UUU.         |   |  |   | estoration of Viral Immunity in Im<br><u>Science</u> 257:238-241, 1992.   | nmunodeficient                    | Humans by the Adoptive     |                |  |  |  |  |
|                       | VVV.         | Rock, Ke<br>Peptides  | nneth<br>," <u>Anr</u>   | n, et al., "Deç<br>nu. Rev. Imm         | gradation of Cell Proteins and thunol. 17:739-779, 1999.  | ne Generation o                   | f MHC Class 1-Presented    |                |  |  |  |  |
|                       | www          |   |  |   | "An HLA-DR1 Transgene Confe<br>an Type II Collagen," <u>J. Exp. Me</u>  |                                   |                            |                |  |  |  |  |
|                       | XXX.         |   |  |   | "Long-lasting anti-viral Cytotox<br>popeptides," <u>Vaccine</u> 13(14):13   |                                   | es Induced In Vivo with    |                |  |  |  |  |
|                       | YYY.         |   |  |   | fficiency of peptides and lipoper<br>nmunol. 21:2649-2654, 1991.  | otides for in vivo                | priming of virus-specific  |                |  |  |  |  |
|                       | ZZZ.         |   | Schulz, Manfred., et al., "Peptide-induced Antiviral Protection by Cytotoxic T Cells," <u>Proc. Natl. Acad.</u> Sci. USA 88:991-993, February 1991.  |   |   |                                   |                            |                |  |  |  |  |
|                       | AAAA.        |   |  |   | ation of a Lipopeptide Immunog<br>NIDS Res. Hum. Retroviruses 16  |                                   |                            |                |  |  |  |  |
|                       |              |   |  |   | Helper-cytotoxic T Lymphocyte (CTL) Determinant Linkage Required for CTL in vivo with Peptide Vaccine Constructs," J. Immunol. 152:549-556, |                                   |                            |                |  |  |  |  |
|                       | CCCC.        | Stratton, Kathleen R., et al., <u>Vaccines for the 21<sup>st</sup> Century: A tool for Decisionmaking</u> . Beth National Academy Press, 2001, pp. ix-xi. |  |   |   |                                   |                            |                |  |  |  |  |
|                       | DDDD.        |   | nd Po  |   | gation of Protein to Immunostir<br>in of Cell-mediated and Humora   |                                   |                            |                |  |  |  |  |
| Examiner<br>Signature |              |   |  |   | citation is in conformance with MP  | Date<br>Considered                |                            |                |  |  |  |  |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Unique citation designation number. 2Applicant is to place a check mark here if English language Translation is attached.

| 6.                    | ,            | •   |                     |   | Complete if Know           | wn                              |                |  |  |  |
|-----------------------|--------------|---|---------------------|---|----------------------------|---------------------------------|----------------|--|--|--|
| ,                     |              |   |                     | Application Number  | 10/603,094                 |                                 |                |  |  |  |
|                       |              | N DISCLOS   |                     | Filing Date   | June 25, 2003              | 3                               |                |  |  |  |
| SIAI                  | EMENI        | BY APPLIC   | ANI                 | First Named Inventor  | Don J. DIAMO               | DND                             |                |  |  |  |
|                       |              |   |                     | Group Art Unit  | 1645                       |                                 |                |  |  |  |
|                       |              |   |                     | Examiner Name   | To Be Assigned             |                                 |                |  |  |  |
| Sheet                 | 8            | of  | 8                   | Attorney Docket Number  | 1954-410                   |                                 |                |  |  |  |
|                       |              |   | NON PA              | TENT LITERATURE DOCU!   | MENTS                      |                                 |                |  |  |  |
| Examiner<br>Initials* | Cite<br>No.1 |   |                     | uthor (in CAPITAL LETTERS), title ournal, serial, symposium, catalog, publisher, city and/or country v  | etc.), date, page(s),      |                                 | T <sup>2</sup> |  |  |  |
|                       | EEEE.        |   |                     | cutting Edge: Induction of Enhan<br>eting of a Model Tumor Antigen  |                            |                                 |                |  |  |  |
|                       | FFFF.        | Cytotoxic T l   | ymphocyte (         | rgeting of HIV-1 Antigens for Ra<br>CTL) Recognition and the Induc<br>kp. Med. 185(5):909-920, 1997.  |                            |                                 |                |  |  |  |
|                       | GGGG.        |   |                     | ipopeptide Particles as the Ir<br>s," <u>Vaccine</u> 17:675-685, 1999   |                            | Active Component of             |                |  |  |  |
|                       | нннн.        |   | f <i>HLA-A2.1</i> T | Phenotypical and Functional Ch<br>ransgenic, H-2KbnullDbnull Do   |                            |                                 |                |  |  |  |
|                       | IIII.        | Varshavsky,<br>93:12142-12  |                     | The N-end Rule: Functions, My   | steries, Uses," <u>Pro</u> | oc. Natl. Acad. Sci. U.S.A.     |                |  |  |  |
|                       | JJJJ.        | Antiretrovira   | Therapy Ma          | "Human Immunodeficiency Viru<br>intain Activated CD8+ T Cell Su<br>virus," <u>J. Infect. Dis</u> . 184:256-26   | bsets as a Strong          |                                 |                |  |  |  |
|                       | KKKK.        | Vitiello, Antonella, et al., "Comparison of Cytotoxic T Lymphocyte Responses Induced by Peptide or DNA Immunization: Implications on Immunogenicity and Immunodominance," <u>Eur. J. Immunol.</u> 27:671-678, 1997. |                     |   |                            |                                 |                |  |  |  |
|                       | LLLL.        | of Allogeneio   | Bone Marro          | 'Reconstitution of Cellular Immunity Against Cytomegalovirus in Recipients by by Transfer of T-Cell Clones from the Donor," The New England Journal 3-1044, October 19, 1995. |                            |                                 |                |  |  |  |
|                       | мммм.        | Wentworth, Peggy, et al. "In Vitro induction of Primary, Antigen-Specific CTL from Human Peripheral Blood Mononuclear Cells Stimulated with Synthetic Peptides," Molecular Immunology 32(9):603-612, 1995.          |                     |   |                            |                                 |                |  |  |  |
|                       | NNNN.        |   |                     | A-A2 Molecules in an Antigen-pr<br>les," <u>Nature</u> 356:443-446, April   |                            | Cell Contain Signal             |                |  |  |  |
|                       | 0000.        | Freund's Adj  | uvant (CFA)         | , "Histopathological Studies on t<br>, Bacterial Lipopolysaccharide (l<br>64:265-271, 1991.   |                            |                                 |                |  |  |  |
|                       | PPPP.        | Dominated b   | y Structural        | e Human Cytotoxic T-Lymphocy<br>Protein pp65: Frequency, Speci<br>70(11):7569-7579, Nov. 1996.  |                            |                                 |                |  |  |  |
|                       | QQQQ.        | Zaia, John A<br>pp. 339-355   |                     | tus of Cytomegalovirus Preventi   | on and Treatmen            | nt in 2000," <u>Hematology,</u> |                |  |  |  |
| Examiner<br>Signature |              |   |                     | r or not elitation is in conformance  | Date<br>Considered         |                                 |                |  |  |  |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1Unique citation designation number. 2Applicant is to place a check mark here if English language Translation is attached.